Pharmaceutical News

RSS

AstraZeneca’s ticagrelor receives Class I recommendation from ESC

AstraZeneca today announced that ticagrelor, an oral antiplatelet medicine, received a Class I recommendation from the European Society of Cardiology (ESC) in the revised "Guidelines on the Management of Acute Myocardial Infarction in Patients Presenting with Persistent ST-Segment Elevation (STEMI)" guidelines.

29 Aug 2012

New method simplifies pharmaceutical production of proteins

Engineering researchers at the University of Arkansas have developed a method to simplify the pharmaceutical production of proteins used in drugs that treat a variety of diseases and health conditions, including diabetes, cancer, arthritis and macular degeneration.

29 Aug 2012

Voters need more information on free trade agreement that could impact drug prices

In an opinion piece in the Guardian's "Comment is Free" blog, Dean Baker, co-director of the Center for Economic and Policy Research, discusses potential policies contained within the "Trans-Pacific Partnership Agreement (TPP), a pact that the United States is negotiating with Australia, Canada, Japan and eight other countries in the Pacific region."

29 Aug 2012

Top 10 reasons to avoid flu shots this year

It's the gift that keeps on giving, from early fall, through the holiday season and into late spring. It's seasonal flu, caused by a virus that can fly through the air, hitch a ride on a handshake, hug or kiss, and is extremely good at infecting people and making them sick.

29 Aug 2012

TaiMed, WuXi enter ibalizumab manufacturing agreement

WuXi PharmaTech today announced that it has a contract manufacturing agreement with TaiMed Biologics Inc. for the manufacture of ibalizumab (TMB-355) in support of Phase 2 and Phase 3 clinical trials globally.

29 Aug 2012

Acorda’s GGF2 can improve erectile function after cavernous nerve damage

Acorda Therapeutics, Inc. announced data from a preclinical study showed that treatment with Glial Growth Factor 2 (GGF2) improved erectile function in an animal model following a cavernous nerve (CN) injury, a common complication of prostate surgery.

29 Aug 2012

MMV390048 shows potent activity against multiple points in malaria parasite's lifecycle

A recently discovered compound from the aminopyridine class not only has the potential to become part of a single-dose cure for all strains of malaria, but might also be able to block transmission of the parasite from person to person, according to a research collaboration involving the Medicines for Malaria Venture (MMV), based in Switzerland, and the Drug Discovery and Development Centre (H3-D) at the University of Cape Town, South Africa.

29 Aug 2012

Elixir Medical’s DESyne BD Novolimus Eluting Coronary Stent System receives CE Mark approval

Elixir Medical Corporation, a developer of product platforms that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that it has received CE Mark approval for its DESyne BD Novolimus Eluting Coronary Stent System for the treatment of coronary artery disease.

29 Aug 2012

GeneTex to introduce new antibody against hypoxia-inducible factor 1alpha

GeneTex, Inc., a leading manufacturer of antibodies, has announced that they will be launching a new antibody against HIF1a (hypoxia-inducible factor 1alpha).

29 Aug 2012

Human Vaccines & Immunotherapeutics Special Focus provides critical view on cancer vaccines

In one of the most comprehensive peer-reviewed discussions on cancer vaccines and immunotherapeutics, a Special Focus in the journal Human Vaccines & Immunotherapeutics provides a critical view on cancer vaccines and a discussion on best approaches for the future.

28 Aug 2012

High doses of vitamin B3 stimulate CEBPE gene, enhance WBCs’ ability to combat staph infections

Cedars-Sinai researchers have found that a common vitamin may have the potential to provide a powerful weapon to fight certain "superbugs," antibiotic-resistant staph infections that health experts see as a threat to public health.

28 Aug 2012

More than 40 plant-based compounds can turn on genes that slow the spread of cancer

More than 40 plant-based compounds can turn on genes that slow the spread of cancer, according to a first-of-its-kind study by a Washington State University researcher.

28 Aug 2012

Nicotinamide may combat antibiotic-resistance staph infections

A new study suggests that nicotinamide, more commonly known as vitamin B3, may be able to combat some of the antibiotic-resistance staph infections that are increasingly common around the world, have killed thousands and can pose a significant threat to public health.

28 Aug 2012

Novartis receives EC approval for Jakavi to treat myelofibrosis

Incyte Corporation today announced that its strategic collaborator, Novartis, received approval from the European Commission for Jakavi (INC424, ruxolitinib), an oral JAK 1 and JAK 2 inhibitor discovered by Incyte, for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.

28 Aug 2012

Janssen licenses rights to Depomed's Acuform gastric retentive drug delivery technology

Depomed, Inc. today announced that Janssen Pharmaceuticals, Inc., has licensed rights to Depomed's Acuform gastric retentive drug delivery technology.

28 Aug 2012

FDA approves Gilead’s Stribild to treat HIV-1 infection

The U.S. Food and Drug Administration today approved Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate), a new once-a-day combination pill to treat HIV-1 infection in adults who have never been treated for HIV infection.

28 Aug 2012

Gilead Sciences receives FDA approval for Stribild to treat HIV-1 infection

Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), a complete once-daily single tablet regimen for HIV-1 infection for treatment-naïve adults.

28 Aug 2012

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

Merz, Inc. today announced the acquisition of CUVPOSA (glycopyrrolate) oral solution for pediatric chronic severe drooling associated with neurologic conditions such as cerebral palsy.

27 Aug 2012

Tris Pharma joins Perrigo to launch first ever store brand ER liquid cough/cold product

Perrigo Company and Tris Pharma, Inc. today announced the commercial launch of a major new store brand product. The new product is equivalent to Delsym extended–release oral liquid suspension containing dextromethorphan polistirex and will be marketed under major U.S. retailer and wholesalers' store brands or own label brands.

27 Aug 2012

Mallinckrodt receives FDA approval for 32 mg tablet strength of EXALGO

The U.S. Food and Drug Administration (FDA) has notified Mallinckrodt, the pharmaceuticals business of Covidien, that it has approved a 32 mg tablet strength of EXALGO (hydromorphone HCI) Extended-Release Tablets (CII) for opioid-tolerant patients with moderate-to-severe chronic pain requiring continuous around-the-clock opioid analgesia for an extended period of time.

27 Aug 2012

Pharmaceutical News

AstraZeneca’s ticagrelor receives Class I recommendation from ESC

New method simplifies pharmaceutical production of proteins

Voters need more information on free trade agreement that could impact drug prices

Top 10 reasons to avoid flu shots this year

TaiMed, WuXi enter ibalizumab manufacturing agreement

Acorda’s GGF2 can improve erectile function after cavernous nerve damage

MMV390048 shows potent activity against multiple points in malaria parasite's lifecycle

Elixir Medical’s DESyne BD Novolimus Eluting Coronary Stent System receives CE Mark approval

GeneTex to introduce new antibody against hypoxia-inducible factor 1alpha

Human Vaccines & Immunotherapeutics Special Focus provides critical view on cancer vaccines

High doses of vitamin B3 stimulate CEBPE gene, enhance WBCs’ ability to combat staph infections

More than 40 plant-based compounds can turn on genes that slow the spread of cancer

Nicotinamide may combat antibiotic-resistance staph infections

Novartis receives EC approval for Jakavi to treat myelofibrosis

Janssen licenses rights to Depomed's Acuform gastric retentive drug delivery technology

FDA approves Gilead’s Stribild to treat HIV-1 infection

Gilead Sciences receives FDA approval for Stribild to treat HIV-1 infection

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

Tris Pharma joins Perrigo to launch first ever store brand ER liquid cough/cold product

Mallinckrodt receives FDA approval for 32 mg tablet strength of EXALGO

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News